A

Alcon

Eye care products and vision solutions

Production Technician - Afternoon shift

Full-TimeDeadline 11/30/26
A$68.9k/yr+ 8% bonus + 15% afternoon-shift loading
Entry
Bachelor's, Certification
Mulgrave, Australia
In Person
Manufacturing & Production OperationsProduct Assembly

About the job

Requirements
  • High School Certificate with strong results in science or technology subjects is desirable but not essential.
  • A technical certification in Electronics, Mechanical Engineering Technology, Mechatronics, Optical Technology/Photonics, or Precision Manufacturing is desirable but not essential.
  • Expertise in precision assembly techniques.
  • Proficiency in using hand tools and precision measuring instruments.
  • Ability to read and follow complex work instructions and technical drawings.
  • Familiarity with Microsoft Office Suite, including Word and Excel, for documentation and reporting.
  • Strong attention to detail and manual dexterity.
  • Strong communication and teamwork abilities.
  • A proactive, adaptable approach to problem-solving.
  • Commitment to workplace safety and quality standards.
  • Ability to adhere to Good Manufacturing Practices in medical device production.
  • Right to live and work in Australia.
Responsibilities
  • Assemble complex micro-optical and electromechanical components following detailed work instructions.
  • Operate custom automation equipment for precision assembly processes.
  • Troubleshoot sub-assemblies and report quality issues.
  • Collaborate with Engineering and New Product Introduction teams on prototype builds.
  • Contribute to 5S and continuous improvement initiatives.
  • Operate and maintain automated assembly equipment.
  • Work afternoon shift from 2 p.m. to 10 p.m.
Desired Qualifications
  • Experience with clean room operations.

About the company

Alcon provides eye care products and vision solutions to improve how people see. It develops and manufactures devices and consumables for eye health, including cataract surgery equipment and intraocular lenses, retinal health therapies, and contact lenses, distributed through eye care professionals, hospitals, and consumers. The products work by supporting eye surgery, protecting and restoring vision, or correcting vision with lens-based options, backed by research and development and a global distribution network. Alcon differentiates itself with a broad, end-to-end portfolio across the eye care continuum, a strong emphasis on research and development, strategic partnerships with healthcare providers, and a commitment to diversity and inclusion. Its goal is to enhance vision and quality of life by delivering reliable, high-quality eye care solutions and advancing the science of eye health.

Company Size

10,001+

Company Stage

IPO

Headquarters

Geneva, Switzerland

Founded

1945

Get referred to Alcon

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Systane PRO PF launched in Canada on September 28, 2026, extending premium dry-eye pricing.
  • UNITY CS and UNITY M shipped in September 2026, expanding Alcon's installed base.
  • Q2 2026 sales rose 8%, while core EPS grew 11% and cash generation stayed strong.

What critics are saying

  • Alcon discontinued PowerVision IOLs in August 2026 after unpredictable postoperative vision outcomes.
  • Implantables grew only 1% constant currency in Q2 2026, signaling cataract competition.
  • If UNITY adoption slows, Alcon depends on mature cataract tools and Systane cash flow.

What makes Alcon unique

  • Alcon's UNITY surgical platform integrates cataract, vitreoretinal, and microscope workflows across 2026 launches.
  • Systane's preservative-free dry-eye franchise leads global artificial tears and deepens consumer reach.
  • Alcon sells across 140 countries, balancing surgical devices with recurring vision-care consumables.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Medical, dental, & vision coverage
  • HSA Medical Plan
  • PTO
  • Paid Parental leave
  • 401k
  • Retirement Plan Company Contribution
  • Low payroll deductions
  • Tuition Reimbursement Program
  • Annual Bonus
  • Free Family Contact Lens Program
  • 12 Company Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

11%

1 year growth

11%

2 year growth

11%
Business Wire
Oct 20th, 2026
Alcon buys Neurotech for $550M to add first FDA-approved MacTel therapy

Alcon has acquired Neurotech Pharmaceuticals for $550 million, adding a rare eye disease therapy to its retina portfolio. The Geneva-based eye care company may owe further contingent payments, including on commercial milestones. Neurotech's ENCELTO is the first and only US Food and Drug Administration (FDA) approved treatment for adults with idiopathic Macular Telangiectasia Type 2 (MacTel). The FDA approved it in March 2025, and it is available only in the US. MacTel is a progressive retinal disease that causes irreversible central vision loss. About 25,000 people in the US have been diagnosed, with 2,000-3,000 new cases each year. Alcon expects the deal to be slightly dilutive to core diluted earnings per share in 2027, and accretive after that.

Associated Press
Oct 16th, 2026
FDA approves Alcon's Brytly eye drops, lasting up to 50% longer than Lumify

Alcon said the US Food and Drug Administration (FDA) has approved BRYTLY Redness Reliever Eye Drops, a new over-the-counter product for eye redness. The Geneva-based eye care company announced the approval on October 16, 2026. One drop works in a minute and lasts up to 12 hours, Alcon said. Based on label claims, that is up to 50% longer than Lumify, which lasts up to eight hours. BRYTLY contains no bleaches or dyes. Studies showed a low risk of redness rebound when used as directed. "This FDA approval marks an exciting milestone for Alcon," said Jonathan Balch, general manager of Ocular Health & Pharmaceuticals. The drops should reach major US retailers and online stores in the coming months, with other markets to follow.

Yahoo Finance
Sep 28th, 2026
Alcon launches Systane PRO PF for 12-hour dry eye relief in Canada

Alcon has launched Systane PRO Preservative-Free in Canada, its longest-lasting dry eye relief formula. The triple-action eye drops provide up to 12 hours of symptom relief for all types of dry eyes. The formula contains hyaluronic acid, HP-guar, nano-sized lipids, and propylene glycol to hydrate, restore, and protect dry eyes. It works by covering the eye surface for instant hydration, providing long-lasting lubrication, and stabilising the tear film to prevent evaporation. Dry eye disease affects an estimated 6 million Canadians and 1.6 billion people globally. Systane is the number one global brand of artificial tears. The new preservative-free formulation addresses symptoms caused by ageing, environmental factors, and digital device use.

Financial Post
Sep 28th, 2026
Introducing Systane(R) PRO PRESERVATIVE-FREE: Alcon's longest lasting, triple-action formula for up to 12 hours of Dry Eye symptom relief.

Introducing Systane(R) PRO PRESERVATIVE-FREE: Alcon's longest lasting, triple-action formula for up to 12 hours of Dry Eye symptom relief. Business Wire Published Sep 28, 2026 * Formulated with hyaluronic acid, Systane(R) PRO PRESERVATIVE-FREE instantly hydrates dry eyes[1] * Systane(R) PRO PF is a multi-dose preservative-free triple action formula that hydrates, restores and protects all types of dry eyes[2-4] * The latest addition to the #1 global consumer brand of artificial tears[5] is now available in Canada TORONTO - Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced the launch of Systane(R) PRO Preservative-Free (PF) in Canada as Systane's most advanced formula. Systane PRO PF is the longest lasting dry eye symptom relief eye drop for all types of dry eye in the Systane portfolio with a unique triple action, preservative-free formula that provides up to 12 hours of dry eye relief.[1*] The product is now available in Canada. Story continues below Dry eye disease (DED) is one of the most common ocular surface disorders, affecting an estimated 6 million people in Canada and 1.6 billion globally.[6] Building on Systane's legacy as the #1 global brand of artificial tears,[5] the new formulation includes HP-guar, hyaluronic acid (HA), nano-sized lipids, and the demulcent propylene glycol to hydrate, restore, and protect dry eyes, providing rapid and continued dry eye symptom relief from the first drop.[2-4, 7-9*] "At Alcon, we are committed to ensuring that dry eye sufferers can get the relief they deserve, which is why we are proud to unveil Systane PRO PF, the longest lasting dry eye symptom relief eye drop in the Systane portfolio," said Vanessa Johari Hansen, Country Franchise Head, Vision Care, Alcon Canada.[2] "Systane PRO's PF formula works to provide sustained hydration, restore tear film stability, and protect against further irritation of dry eyes."[3-4] Patients with dry eyes often experience symptoms when moisture retention and tear stability are impacted by a variety of factors, including aging, environment, and digital device use.[10] Combatting these everyday challenges, this new formula covers the surface of the eye for instant hydration and soothing dry eye relief, protects from and prevents further dryness of the eye with long-lasting lubrication,[**] and stabilizes the tear film to prevent from further evaporation.[2-4^] "I have witnessed firsthand how disruptive, and at times debilitating, dry eye symptoms can be," said Dr. François Piuze, optometrist and co-owner of the Eye Am clinics in Quebec City and Montreal. For Eye Care Professionals, pinpointing long-lasting solutions for patients to address the symptoms of this complex and multifactorial disease is critical. That is why it is so exciting that patients in Canada can now experience up to 12 hours of dry eye symptom relief with Systane PRO PF."[2*] As part of Alcon's ongoing efforts to educate audiences around the effects and treatment of DED, the organization recently partnered with the Tear Film & Ocular Surface Society (TFOS) to develop the DEWS III report, building upon the globally recognized body of work that has helped shape clinical understanding of DED. "The report highlights the multifactorial and symptomatic nature of the disease and the importance of providing personalized treatment strategies," notes Dr. Piuze. "This includes first-line foundational treatment options with ingredients like HP-guar and hyaluronic acid (HA), based on individual patient risk factors and disease subtypes." Story continues below To learn more about Systane PRO PF, please visit https://systane.myalcon.com/en-ca/products/systane-pro-preservative-free/ Important Information for the Systane(R) Family of Products Systane lubricant eye drops have been clinically proven to reduce the symptoms of dry eye, providing fast, long-lasting relief and comfort. Systane is the #1 global consumer brand of artificial tears.[5] Systane(R) COMPLETE provides symptom relief for people who suffer from evaporative dry eye, aqueous tear-deficient dry eye or mixed dry eye. Systane(R) ULTRA is designed for dry eye with aqueous deficient patients. Systane(R) BALANCE lubricant eye drops are designed specifically for patients with evaporative dry eye associated with meibomian gland dysfunction. Systane(R) HYDRATION gives long-lasting relief of dry eye symptoms for moderate or chronic sufferers or patients who are recovering from corneal or other eye surgery. About Alcon Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people's lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries and territories each year living with conditions like cataracts, glaucoma, retinal diseases, and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals, and programs that advance access to quality eye care. Learn more at *47% of patients experience meaningful symptom relief at 12 hours, N = 153. **Dose: 4 times a day. ^Improvement in NITBUT demonstrated at Day 30 compared to baseline. Dosed 4 times a day. N =316; (p<0.0001). References * Alcon data on file, 2025. REF-26802. * SYSTANE Hydration (HA/HPG) provided effective hydration and lubrication and demonstrated prolonged retention of effect. (p.1). * Rangarajan R, Ketelson H. Preclinical evaluation of a new hydroxypropyl-guar phospholipid nanoemulsion-based artificial tear formulation in models of corneal epithelium. J Ocul Pharmacol Ther. 2019;35(1):32-37. doi:10.1089/jop.2018.0031. * Craig JP, Muntz A, Wang MTM, Luensmann D, Tan J, Trave Huarte S, Xue AL, Jones L, Willcox MDP, Wolffsohn JS. Developing evidence-based guidance for the treatment of dry eye disease with artificial tear supplements: A six-month multicentre, double-masked randomised controlled trial. Ocul Surf. 2021 Apr;20:62-69. doi: 10.1016/j.jtos.2020.12.006. Epub 2021 Jan 2. PMID: 33401019. * Alcon data on file, 2025. REF-26802. * Caffery B, Srinivasan S, Reaume CJ, Fischer A, Cappadocia D, Siffel C, Chan CC. Prevalence of dry eye disease in Ontario, Canada: A population-based survey. Ocul Surf. 2019 Jul;17(3):526-531. doi: 10.1016/j.jtos.2019.02.011. Epub 2019 Feb 27. PMID: 30825521. * Kesavan S, Prud'homme RK. Rheology of guar and (hydroxypropyl) guar crosslinked by borate. Macromolecules. 1992;25(7):2026-2032.doi:10.1021/ma00033a029. * Ubels JL, Clousing DP, Van TA, et al. Pre-clinical investigation of the efficacy of an artificial tear solution containing hydroxypropylguar as a gelling agent. Curr Eye Res. 2004;28(6):437-444. doi:10.1080/02713680490503787. * Rangarajan R, Kraybill B, Ogundele A, Ketelson HA. Effects of a hyaluronic acid/hydroxypropyl guar artificial tear solution on protection, recovery, and lubricity in models of corneal epithelium. J Ocul Pharmacol Ther. 2015;31(8):491-497. doi:10.1089/jop.2014.0164. * Market Scope LLC. 2020 Dry Eye Products Report: A Global Market Analysis for 2019 to 2025. St. Louis, MO. Connect with us on (C) 2026 Alcon Inc. CA-SAF-2600098 View source version on businesswire.com: Media Relations

Opti-Guide
Sep 7th, 2026
Alcon launches UNITY M, a premium ophthalmic microscope delivering precise control.

Alcon launches UNITY M, a premium ophthalmic microscope delivering precise control. Alcon announced the initial commercial launch of UNITY M, an Alcon brand premium surgical microscope that delivers precise control to ophthalmic surgeons, in select markets including the U.S. and Japan followed by Europe.[1,2,4] UNITY M will be featured at the upcoming Congress of the European Society of Cataract and Refractive Surgeons (ESCRS). The microscope is the latest addition to Alcon's UNITY platform, combining advanced optics, novel illumination, improved ergonomics, and intuitive usability in a modular design that enables practice-specific customization and future scalability.[1-3,5-7, ,‡,§] "The idea behind the UNITY platform is to develop clinic-based and operating room equipment solutions with a seamless user experience that improve surgical workflows," said Ian Bell, SVP and Chief Operating Officer of Alcon. "By partnering closely with Eye Care Professionals to understand their most significant unmet needs, we developed UNITY M to provide a flexible, future-ready visualization platform that gives surgeons precise control and personalization in the operating room."